AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Industrial Minerals Ltd

0.120

+0.0054.35%

Volume:4K

Turnover:486

Market Cap:12.04M

PE:-13.12

High:0.120

Open:0.120

Low:0.120

Close:0.115

52wk High:0.200

52wk Low:0.092

Shares:100.32M

Float Shares:42.54M

Volume Ratio:0.51

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.009

EPS(LYR):-0.030

ROE:-24.45%

ROA:-13.01%

PB:4.60

PE(LYR):-4.02

Loading ...

Overview Company News Filings

Industrial Minerals Ltd-Proposed Issue of Securities - Ind

THOMSON REUTERS

BRIEF-Industrial Minerals Seeks Trading Halt

Industrial Minerals Ltd - Trading Halt Pending Proposed Acquisition and Capital Raising Announcement

THOMSON REUTERS

Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs

OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease

Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development

3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone

Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC

Belief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese Patients

Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs

Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases

Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models

ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis

HBM Holdings Gets China IND Approval for Atopic Dermatitis Drug Candidate

MT Newswires Live

XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication

Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/IND.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IND.AU\",,,,,undefined,":{"symbol":"IND.AU","market":"AU","secType":"STK","nameCN":"Industrial Minerals Ltd","latestPrice":0.12,"timestamp":1787531086051,"preClose":0.115,"halted":0,"volume":4049,"delay":0,"changeRate":0.04347826086956513,"nameEN":"Industrial Minerals Ltd","floatShares":42536073,"shares":100322500,"eps":-0.009145,"marketStatus":"Trading","change":0.005,"latestTime":"08-24 10:57:06 AEST","open":0.12,"high":0.12,"low":0.12,"amount":486,"amplitude":0,"askPrice":0.12,"askSize":47617,"bidPrice":0.105,"bidSize":100500,"shortable":3,"etf":0,"ttmEps":-0.009145,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787551200000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.115,"openAndCloseTimeList":[[1787529600000,1787551200000]],"volumeRatio":0.512202,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IND.AU","preClose":0.115,"auctionPrice":0.12,"auctionVolume":4049,"auctionTime":1787529546111,"referenceTime":1786962603093,"auction":1,"marketStatus":"盘前竞价","timestamp":1787529546111}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IND.AU\",,,,,undefined,":{"symbol":"IND.AU","floatShares":42536073,"roa":"-13.01%","roe":"-24.45%","lyrEps":-0.02987,"volumeRatio":0.512202,"shares":100322500,"dividePrice":0,"high":0.12,"amplitude":0,"preClose":0.115,"low":0.12,"week52Low":0.092,"pbRate":"4.60","psRate":"14383.15","week52High":0.2,"institutionHeld":0,"latestPrice":0.12,"committee":0.357035,"eps":-0.009145,"divideRate":0,"volume":4049,"delay":0,"ttmEps":-0.009145,"open":0.12,"prevYearClose":0.13,"prevWeekClose":0.115,"prevMonthClose":0.096,"prevQuarterClose":0.14,"fiveDayClose":0.12,"twentyDayClose":0.12,"sixtyDayClose":0.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635221837","title":"Industrial Minerals Ltd-Proposed Issue of Securities - Ind","url":"https://stock-news.laohu8.com/highlight/detail?id=2635221837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635221837?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:54","pubTimestamp":1778630087,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUE58T4BF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634241054","title":"BRIEF-Industrial Minerals Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2634241054","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634241054?lang=en_us&edition=fundamental","pubTime":"2026-05-11 07:06","pubTimestamp":1778454412,"startTime":"0","endTime":"0","summary":"BRIEF-Industrial Minerals Seeks Trading HaltMay 11 (Reuters) - Industrial Minerals Ltd IND.AX:TRADING HALT PENDING PROPOSED ACQUISITION AND CAPITAL RAISING ANNOUNCEMENTFurther company coverage: IND.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260510:nFWN41L1X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND.AU","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634424106","title":"Industrial Minerals Ltd - Trading Halt Pending Proposed Acquisition and Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2634424106","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634424106?lang=en_us&edition=fundamental","pubTime":"2026-05-11 07:06","pubTimestamp":1778454387,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260510:nFWN41L1X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628733305","title":"Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs","url":"https://stock-news.laohu8.com/highlight/detail?id=2628733305","media":"prnewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628733305?lang=en_us&edition=fundamental","pubTime":"2026-04-18 08:30","pubTimestamp":1776472200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, April 18, 2026 /PRNewswire/ -- Antengene Corporation Limited  , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that it has released present results from three novel programs in poster presentations at the 2026 American Association for Cancer Research Annual Meeting . The presentations will feature ATG-125 , an IO + ADC dual-function molecule being developed for the treatment of solid tumors, as well as two investigational T cell engagers  developed using the company's proprietary AnTenGager TCE platform, including ATG-106  for ovarian and kidney cancers, and ATG-112  for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC.","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-presents-three-novel-programs-at-aacr-2026-highlighting-next-generation-adc-and-antengager-tces-302745781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065731478.USD","BK4006","IE0031619046.USD","BK4231","BK4080","BK4187","IE00B7SZL793.SGD","CRS","CRS.AU","IE00B66KJ199.SGD","IE00B19Z4B17.USD","IND","LU0963586101.USD","IND.AU","BK7095","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626262186","title":"OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2626262186","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626262186?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:00","pubTimestamp":1775732400,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md., April 9, 2026 /PRNewswire/ --OncoC4 Inc., a late clinical stage biopharmaceutical company, today announced first participant's dosing following the clearance of the Investigational New Drug  application for a Phase 1/2 clinical trial of ONC-841, the company's investigational Alzheimer's disease therapy by the National Medical Product Administration . The clinical trial registration number is CTR20260866.ONC-841 is the world's first and only clinical stage anti-SIGLEC 10 antibody. The drug was initially developed, and is in a Phase 2 trial, for patients with solid tumors. New preclinical research by OncoC4 has revealed ONC-841's novel activity in normalizing microglia's function in clearance of pathogenic protein aggregates in the brain . Benefitting from safety data from the oncology study, the new Phase 1/2 AD clinical trial received accelerated clearance to test the safety and clinical activity of the product for AD treatment.The first study participant was successful","market":"us","thumbnail":"https://mma.prnewswire.com/media/2787251/OncoC4_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2787251/OncoC4_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/oncoc4-announces-first-participants-dosing-in-phase-12-clinical-trial-of-onc-841-for-the-treatment-of-alzheimers-disease-302737593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","IND.AU","BK4139","IND","BK4588","BK4526","BK4585","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625493771","title":"Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2625493771","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625493771?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:00","pubTimestamp":1775559600,"startTime":"0","endTime":"0","summary":"-Fixed-dose combination of ASC30 and ASC39  tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study. The fixed dose combination had excellent oral bioavailability, drug exposure and a half-life of up to 12 hours. These data support ASC30_39 FDC tablets as a potential novel one-pill-once-daily therapy for obesity.-ASC30_39 FDC demonstrated excellent compatibility between ASC30 and ASC39 when combined together, with room temperature stability and a small pill size.-ASC30 is a Phase III-ready oral small molecule GLP-1R agonist that had a favorable gastrointestinalprofile with half the rate of vomiting vs. orforglipron, when both drugs are dosed with weekly titration.-ASC39, an oral small molecule amylin-selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.-Submission of an Investigational New Drug Application  to the U.S. Food and D","market":"other","thumbnail":"https://mma.prnewswire.com/media/2935737/Ascletis_Pharma_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2935737/Ascletis_Pharma_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-announces-fixed-dose-combination-of-asc30-once-daily-oral-small-molecule-glp-1r-agonist-and-asc39-once-daily-oral-small-molecule-amylin-selective-amylin-receptor-agonist-for-clinical-development-302735619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","GLP","BK4590","BK7095","BK4144","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623589931","title":"3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2623589931","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623589931?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:13","pubTimestamp":1774959180,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc.  today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a high-quality performance with both quantitative and qualitative growth: annual revenue hit RMB 17.7 billion, a historic breakthrough past the RMB 10 billion mark, representing a 94.3% year-on-year  increase; net profit attributable to shareholders of the parent company reached RMB 8.48 billion, surging 305.8% YoY; adjusted net profit attributable to shareholders of the parent company stood at RMB 8.45 billion, a 264.6% YoY rise. The company's profitability achieved a leap-forward growth, demonstrating robust growth momentum.Under the collaboration agreement, 3SBio granted Pfizer exclusive global development and commercialization rights to SSGJ-707, with the total potential deal value exceeding US$6 billion. The company is also entitled to tiered double-digi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/3sbio-announces-2025-annual-results-dual-engines-of-innovative-rd-and-global-collaboration-propel-revenue-past-rmb-10-billion-milestone-302729335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999003800.SGD","IND.AU","LU1894683264.USD","SG9999001176.USD","BK4007","IBD","SG9999013999.USD","BK7095","SG9999002232.USD","BK4581","CLDT","IE00B19Z3581.USD","IND","LU0321505439.SGD","BK4534","LU0225284248.USD","LU0170899867.USD","BK4588","LU0456855351.SGD","BK4592","BK4568","IE00BLSP4452.SGD","ITP","BRVO","BK1583","LU1894683348.USD","LU0321505868.SGD","LU0985481810.HKD","ADA.AU","PFE","01530","BK1161","SAA","BK7016","IE0002270589.USD","IE00B19Z3B42.SGD","BK4077","BK4585","SLE","BK4181","LU0306806265.USD","LU1883839398.USD","BK1593","LU1066053197.SGD","LU0289739699.SGD","BK4599","HK0000165453.HKD","IE000M9KFDE8.USD","BK4218","SG9999011175.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621068695","title":"Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2621068695","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621068695?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:24","pubTimestamp":1774344240,"startTime":"0","endTime":"0","summary":"CHENGDU, China, March 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  today announced that the Investigational New Drug  application for SKB103, its self-developed novel bispecific antibody-drug conjugate with combined Tumor-Associated Antigen-targeting and Immuno-Oncology mechanisms , has been approved by the Center for Drug Evaluation  of the National Medical Products Administration  of China for the treatment of advanced solid tumors. The approval marks SKB103 as the Company's first TAA-PD-L1 bsADC candidate and its second bsADC program for tumor therapy to enter the clinical stage, following SKB571.Kelun-Biotech  is a holding subsidiary of Kelun Pharmaceutical , which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-receives-ind-approval-for-skb103-a-novel-taa-pd-l1-bispecific-adc-302723152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND.AU","LU1169589451.USD","BK4023","IND","LU1064131003.USD","BK7050","BK4017","LU1223082196.USD","BK4231","XBI","BK7095","BK4080","LU2148510915.USD","002422","BK4585","LU1064130708.USD","BK4588","CDE.AU","CDE","ADC","LU1223082519.USD","BK0060","LU1223083913.SGD","LU1979443071.USD","PD","BK0239","LU1934453819.USD","BK4581","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621722962","title":"Belief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2621722962","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621722962?lang=en_us&edition=fundamental","pubTime":"2026-03-23 14:02","pubTimestamp":1774245720,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 23, 2026 /PRNewswire/ -- Belief BioMed  and Grand Life Sciences Group Co., Ltd.  today announced an exclusive collaboration agreement. Under the agreement, Belief BioMed will grant Grand Life Sciences the rights to commercialize its investigational product, BBM-H803, in Mainland China, Hong Kong China, Macau China, and Taiwan China. The collaboration underscores the shared commitment of both sides to leverage their respective strengths and resources in their respective fields,to accelerate the commercialization process of the product,help hemophilia A patients access innovative treatment option, and jointly promote the development of the gene therapy industry. The agreement was signed by Xiao Xiao, Co-founder, Chairman and CSO of Belief BioMed, and Zenghui, Feng, Chairman of Grand Life Sciences.Signing Ceremony for the Exclusive Commercial Collaboration Between Belief BioMed and Grand Life Sciences . About Hemophilia AHemophilia A is a genetic disorder caused by the def","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2939687/image1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2939687/image1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/belief-biomed-and-grand-life-sciences-announced-exclusive-commercial-partnership-in-the-field-of-hemophilia-a-bringing-innovative-gene-therapy-to-chinese-patients-302721797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLA.AU","IND.AU","BK4183","IND","IE0009354923.USD","ODD","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620026984","title":"Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs","url":"https://stock-news.laohu8.com/highlight/detail?id=2620026984","media":"prnewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620026984?lang=en_us&edition=fundamental","pubTime":"2026-03-18 08:30","pubTimestamp":1773793800,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, March 18, 2026 /PRNewswire/ -- Antengene Corporation Limited  , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that it will present results from three preclinical studies in poster presentations at the 2026 American Association for Cancer Research Annual Meeting , taking place from April 17th to 22th, at the San Diego Convention Center, California, the United States. The presentations will feature ATG-125 , an IO + ADC dual-function molecule being developed for the treatment of solid tumors, as well as two investigational T cell engagers  developed using the company's proprietary AnTenGager TCE platform, including ATG-106  for ovarian and kidney cancers, and ATG-112  for gynecological tumors, digestive system malignancies, bladder cancers and NSCLC.AT","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-to-present-on-three-preclinical-programs-at-aacr-2026-highlighting-next-generation-adcs-and-antengager-tces-302716126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","CRS.AU","IND","CRS","BK4006","IE00B7SZL793.SGD","LU2065731478.USD","LU0963586101.USD","BK4145","BK7095","IND.AU","BK4187","IE00B66KJ199.SGD","ALPP","IE0031619046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620420768","title":"Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2620420768","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620420768?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:30","pubTimestamp":1773754200,"startTime":"0","endTime":"0","summary":"IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's proprietary mRNA–LNP platform.HONG KONG SAR, Chinaand SHENZHEN, China and CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Innorna, a clinicalstage biotech company advancing RNA medicines, today announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for IN026, an investigational mRNA-based therapy for refractory gout. The IND clearance enables the company to initiate a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IN026 in this currently underserved patient population.IN026 delivers mRNA encoding urate oxidase  to the liver to enable systemic uric acid breakdown.\"Refractory gout remains a severely debilitating condition, and existing biologic treatments are limited by immunogenicity, tolerability challenges, and diminishing efficac","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2934528/Innorna_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2934528/Innorna_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/innorna-announces-fda-clearance-of-ind-for-in026-advancing-mrna-based-therapies-into-chronic-metabolic-diseases-302715658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IND.AU","IND","LABU","BK7095","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620841423","title":"Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2620841423","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620841423?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:00","pubTimestamp":1773741600,"startTime":"0","endTime":"0","summary":"- In a head-to-head cyclic adenosine monophosphate  activation assay vs. eloralintide, oral small molecule amylin receptor agonist ASC39 demonstrated similar selectivity and potency to that of eloralintide. EC50 for human amylin 1 receptor  was 21.4 pM and 21.2 pM for ASC39 and eloralintide, respectively. EC50 for human calcitonin receptor  was 846.1 pM and 1,350.8 pM for ASC39 and eloralintide, respectively. These data indicate ASC39 and eloralintide have similar selectivity for hAMY1R over hCTR.- In a head-to-head diet-induced obese  rat study vs. eloralintide, efficacy of ASC39 oral dosing was comparable to that of eloralintide, demonstrating significant placebo adjusted weight loss of 6.6% and 5.6% for ASC39 and eloralintide, respectively.- Submission of an Investigational New Drug Application  to the U.S. Food and Drug Administration  for ASC39 oral tablets is expected in the third quarter of 2026.Table 1. Once-daily oral administration of ASC39 for 6 consecutive days produced sta","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2935737/Ascletis_Pharma_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2935737/Ascletis_Pharma_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/oral-small-molecule-amylin-receptor-agonist-asc39-demonstrated-eloralintide-like-amylin-selectivity-and-efficacy-in-preclinical-models-302715856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND.AU","IND","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618366608","title":"ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2618366608","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618366608?lang=en_us&edition=fundamental","pubTime":"2026-03-10 06:34","pubTimestamp":1773095640,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited  today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx  – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed.Neeraj Agarwal, MD, Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, Salt Lake City, and ProstACT Global Principal Investigator and Steering Committee member, commented, \"These results reinforce the feasibility of integrating TLX591-Tx with current standard of care therapies for mCRPC, including ARPIs such as enzalutamide or abiraterone, or docetaxel. Hematologic events align with those typically seen in this patient population and therapeutic class, and these cases resolved quickly. The dosimetry profile, along with the low-grade nature of non-hematologic advers","market":"sg","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prostact-global-phase-3-study-part-1-achieves-primary-objectives-302708664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEC.AU","TLX.AU","IND","ASX.AU","BK4526","BK4213","SOC","BK7067","BK4543","RLT.AU","BK7061","SOC.AU","BK7039","BK4139","IND.AU","ASX","BK4141","BK7142","TLX","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618623527","title":"Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623527","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618623527?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:39","pubTimestamp":1773056340,"startTime":"0","endTime":"0","summary":"CHENGDU, China, March 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  and Harbour BioMed  today announced that the National Medical Products Administration  of China has approved the Investigational New Drug  applicationfor SKB575/HBM7575, a long-acting bispecific antibody targeting thymic stromal lymphopoietin and an undisclosed target co-developed by the two parties, forthe treatment of atopic dermatitis.Dr.Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: \"The NMPA's IND approval for HBM7575/SKB575 marks an important step forward in addressing the significant unmet needs in autoimmune diseases such as atopic dermatitis. By targeting TSLP, a key upstream driver of type2 inflammation, and an undisclosed target, HBM7575/SKB575 has the potential to be a best-in-class bispecific antibody for this disease. We look forward to advancing this investigational therapy through clinical development and believe its long-acting profile may offer a d","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-and-harbour-biomed-announce-nmpa-approval-of-ind-application-for-skb575hbm7575-for-the-treatment-of-atopic-dermatitis-302708094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","TSLP","IND.AU","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618564967","title":"HBM Holdings Gets China IND Approval for Atopic Dermatitis Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618564967","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618564967?lang=en_us&edition=fundamental","pubTime":"2026-03-09 16:54","pubTimestamp":1773046462,"startTime":"0","endTime":"0","summary":"HBM Holdings  said China's National Medical Products Administration approved the investigational new drug  application for HBM7575, a drug candidate for the treatment of atopic dermatitis, according to a Monday Hong Kong bourse filing.HBM7575, also known as SKB575, is a long-acting bispecific antibody targeting thymic stromal lymphopoietin and an undisclosed antigen, designed to inhibit immune pathways linked to the skin condition, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK1583","BK7095","IND","IND.AU","02142","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616701288","title":"XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2616701288","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616701288?lang=en_us&edition=fundamental","pubTime":"2026-03-02 08:30","pubTimestamp":1772411400,"startTime":"0","endTime":"0","summary":"- XPOVIO is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service  for the treatment of adult patients with multiple myeloma .- In South Korea, XPOVIO has been approved for three indications across MM and diffuse large B-cell lymphoma , and two of these approved indications have been included in the national reimbursement scheme.SHANGHAI and HONG KONG, March 2, 2026 /PRNewswire/ -- Antengene Corporation Limited  , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that South Korea's National Health Insurance Service  has approved the reimbursement of XPOVIO  in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma  after one prior therapy. The reimbursement has taken effect on March 1, 2","market":"other","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/xpovio-receives-reimbursement-approval-in-south-korea-for-a-second-multiple-myeloma-indication-302700204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND.AU","BK4187","CRS.AU","BK7095","IND","IE00B66KJ199.SGD","CRS","IE0031619046.USD","LU0963586101.USD","BK4006","IE00B19Z4B17.USD","IE00B7SZL793.SGD","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614722974","title":"Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614722974","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614722974?lang=en_us&edition=fundamental","pubTime":"2026-02-25 08:30","pubTimestamp":1771979400,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Feb. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited  , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, announced that it has entered into a clinical collaboration agreement with Shanghai Junshi Biosciences Co., Ltd . Under the collaboration, the parties will jointly evaluate the synergistic therapeutic potential of Antengene's ATG-037, an oral small-molecule CD73 inhibitor, in combination with Junshi Biosciences' JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, in patients with solid tumors in Mainland China, with the goal of identifying clinical signals across multiple tumor types.","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-announces-clinical-collaboration-with-junshi-biosciences-to-explore-the-synergistic-potential-of-atg-037-oral-cd73-inhibitor-in-combination-with-js207-pd-1vegf-bsab-302695694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4187","IE0031619046.USD","BK4023","HCC","ORR","LU0963586101.USD","IND.AU","IE00B66KJ199.SGD","BK4097","LU1169590202.USD","LU2065731478.USD","CRS","IE00B7SZL793.SGD","RCC","LU1169589451.USD","OS","CRS.AU","BK7095","IND","IE00B19Z4B17.USD","PD","ORR.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":37,"code":"91000000","status":"200"}]}}